JointHealth™ express June 6, 2013
New addition to PEI’s medication formulary
Certolizumab pegol (Cimzia®) for the treatment of rheumatoid arthritis (RA) has newly been listed for coverage on Prince Edward Island’s formulary, under the High Cost Drug Program.
Now there are more treatment options available in PEI, which is important because every patient responds differently to disease suppressing or modifying medications.
Certolizumab pegol is a medication used to treat rheumatoid arthritis. It is an anti-TNF medication taken by subcutaneous injection every two weeks (200mg/mL pre-filled syringe).
To learn if certolizumab pegol or other rheumatoid arthritis treatment may be helpful to you, please speak to your rheumatologist or other healthcare provider who is helping you to manage your disease.
Click here to view the most up-to-date version of ACE's Report Card on provincial formulary reimbursement listings for biologic response modifiers.
New addition to PEI’s medication formulary
Certolizumab pegol (Cimzia®) for the treatment of rheumatoid arthritis (RA) has newly been listed for coverage on Prince Edward Island’s formulary, under the High Cost Drug Program.
Now there are more treatment options available in PEI, which is important because every patient responds differently to disease suppressing or modifying medications.
Certolizumab pegol is a medication used to treat rheumatoid arthritis. It is an anti-TNF medication taken by subcutaneous injection every two weeks (200mg/mL pre-filled syringe).
To learn if certolizumab pegol or other rheumatoid arthritis treatment may be helpful to you, please speak to your rheumatologist or other healthcare provider who is helping you to manage your disease.
Click here to view the most up-to-date version of ACE's Report Card on provincial formulary reimbursement listings for biologic response modifiers.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.